PLUR — Pluri Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1158780 ·
Israel
Last close
$2.33
Market Cap
$25.14M
52W High
$3.89
52W Low
$2.22
ADV30
14,981
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 167,000 | 56,000 | -6,536,000 | -5,548,000 | 26,057,000 | 3,419,000 | 39,056,000 |
| Dec 2025 | 198,000 | 86,000 | -6,506,000 | -6,543,000 | 30,596,000 | 4,690,000 | 39,809,000 |
| Sep 2025 | 316,000 | 115,000 | -6,350,000 | -5,850,000 | 33,672,000 | 4,259,000 | 39,319,000 |
| Jun 2025 | 398,000 | 207,000 | -6,621,000 | -7,598,000 | 38,683,000 | 5,895,000 | 39,548,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,361,000
Investing CF
$11,322,000
Financing CF
$10,911,000
CapEx
$-1,328,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.85
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-460,996,000
Inventory
—
Receivables
$99,000
ST Investments
$5,903,000
EBIT TTM
$-26,044,000
Pretax Income TTM
$-26,974,000
Interest Exp TTM
$930,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,079,000
EBITDA
$-25,515,000
Free Cash Flow
$-14,668,375
Enterprise Value
$55,049,644
Total Cash
$9,322,000
Total Debt
$33,628,000
Shares Out
10,789,546
Trailing EPS
$-2.90
Book Value
$-1.78
ROE
—
ROA
-51.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 1,336,000 | -22,176,000 | -22,583,000 | 38,683,000 | 39,548,000 | — | -18,211,000 |
| Jun 2024 | 326,000 | -22,158,000 | -20,888,000 | 39,527,000 | 34,112,000 | — | -18,021,000 |
| Jun 2023 | 287,000 | -27,246,000 | -28,321,000 | 50,797,000 | 35,497,000 | — | -22,857,000 |
| Jun 2022 | 234,000 | -41,593,000 | -41,242,000 | 68,065,000 | 35,879,000 | — | -36,501,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALGS | Aligos Therapeutics, Inc. | $27.53M | $5.11 | — |
| DYAI | DYADIC INTERNATIONAL INC | $29.00M | $0.80 | — |
| EVAX | Evaxion A/S | $30.02M | $3.60 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $30.12M | $0.97 | — |
| INMB | Inmune Bio, Inc. | $34.03M | $1.28 | — |
News headlines (Yahoo Finance, 1h cache)
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
2026-06-02 11:30 · Yahoo
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In
2026-05-30 15:46 · Yahoo
Pluri Insider Ups Holding During Year
2026-05-28 10:56 · Yahoo
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
2026-05-01 20:00 · Yahoo
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
2026-03-26 12:30 · Yahoo
Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
2026-02-18 13:00 · Yahoo
Pluri: Fiscal Q2 Earnings Snapshot
2026-02-12 22:12 · Yahoo
Pluri showcases cell expansion platform as Resbiomed program advances
2026-02-09 15:30 · Yahoo
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
2026-01-22 14:15 · Yahoo
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
2025-12-22 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.